Compass Pathways Plc Total Liabilities

Latest as of December 2025: $263.20 Million USD

Compass Pathways Plc total liabilities. Based on the latest financial reports, Compass Pathways Plc (CMPS) has total liabilities worth $263.20 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Compass Pathways Plc (CMPS) liquidity interval to measure how many days the company can operate on defensive assets alone.

Total Liabilities of Compass Pathways Plc (2018–2025)

Total liabilities of Compass Pathways Plc from 2018 to 2025. This chart illustrates how Compass Pathways Plc's total liabilities have evolved over time, based on quarterly financial data. Explore CMPS strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.

Compass Pathways Plc Competitors by Total Liabilities

The table below lists competitors of Compass Pathways Plc ranked by their total liabilities.

Company Country Total Liabilities
OVH GROUPE UNSP.ADR/1/2
F:7U70
Germany €1.73 Billion
Bank Leumi Le-Israel B.M
TA:LUMI
Israel ILA876.69 Billion
U-Haul Holding Company
NYSE:UHAL
USA $13.87 Billion
Shandong Yisheng Livestock & Poultry Breeding Co Ltd
SHE:002458
China CN¥3.02 Billion
Yunnan Salt & Salt Chemical Industry Co Ltd
SHE:002053
China CN¥8.64 Billion
JM Financial Limited
NSE:JMFINANCIL
India Rs-113.58 Billion
NINGBO HENGSHUAI Co. LTD.
SHE:300969
China CN¥595.89 Million
Netcare
JSE:NTC
South Africa ZAC18.24 Billion

Liability Composition Analysis (2018–2025)

This chart breaks down Compass Pathways Plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see CMPS total assets.

Liquidity & Leverage Metrics

Compass Pathways Plc Total Liabilities Ratios Explained

Compass Pathways Plc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 0.77 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -4.98 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 1.25 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Compass Pathways Plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Compass Pathways Plc (2018–2025)

The table below shows the annual total liabilities of Compass Pathways Plc from 2018 to 2025.

Year Total Liabilities Change
2025-12-31 $263.20 Million +346.32%
2024-12-31 $58.97 Million +17.37%
2023-12-31 $50.24 Million +213.74%
2022-12-31 $16.01 Million -2.86%
2021-12-31 $16.49 Million +139.10%
2020-12-31 $6.89 Million -71.12%
2019-12-31 $23.87 Million -41.43%
2018-12-31 $40.75 Million --

About Compass Pathways Plc

NASDAQ:CMPS USA Medical Care Facilities
Market Cap
$1.16 Billion
Market Cap Rank
#7989 Global
#2397 in USA
Share Price
$8.59
Change (1 day)
+2.14%
52-Week Range
$4.94 - $15.19
All Time High
$59.20
About

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly … Read more